FindMyKOL
Clinical trialNCT07867002RecruitingPhase 3Interventional

Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer

SponsorUNC Lineberger Comprehensive Cancer CenterEnrollment140Endometrial AdenocarcinomaEndometrial CancerMetastatic Endometrial CancerRecurrent Endometrial Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a pragmatic, non-inferiority randomized hybrid decentralized clinical trial. The goal of this study is to determine if one year of maintenance immunotherapy (anti-PD1 agent therapy; pembrolizumab or dostarlimab) is non-inferior to two years of maintenance therapy for patients with advanced/metastatic or recurrent endometrial cancer who have completed the standard course of cytotoxic chemotherapy plus anti-PD1 therapy (chemoimmunotherapy). Our hypothesis is that one year of maintenance therapy will be comparable, or statistically non-inferior, to two years of therapy. This question has clinical importance as there is not a clear optimal duration for maintenance immunotherapy in this setting, and checkpoint inhibitors are associated with their own unique toxicity profile (immune-related adverse events) and incremental costs to patients and the healthcare system at large. Patients who respond favorably to primary therapy and choose to enroll will be randomized (1:1) after completion of chemoimmunotherapy to one-year of maintenance anti-PD1 therapy (1-year arm) or to two-years of maintenance anti-PD1 therapy (2-year arm). The primary endpoint is progression-free survival (PFS) determined over the course of at least 3 years from randomization of patient follow up. Secondary endpoints are overall survival (OS) and incidence of immune-related adverse events (irAE). Finally, exploratory objectives include measuring differences in gut and vaginal microbial profiles and innate immune system (IIS) tumor profiles and correlation with clinical outcomes (PFS, OS).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Unc Health Cancer Care, A Service of Unc Hospitals

    Cary, North Carolina, United States

    Olivia D Lara, MD
    Recruiting
  • Unc Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, United States

    Olivia D Lara, MD, MS
    Recruiting
  • Unc Health Cancer Care, A Service of Unc Hospitals (garner)

    Garner, North Carolina, United States

    Olivia D Lara, MD
    Recruiting
  • Wesley Long Cone Health Cancer Center

    Greensboro, North Carolina, United States

    Glenn Boyles
    Recruiting
  • Unc Health Cancer Care, A Service of Unc Hospitals (raleigh)

    Raleigh, North Carolina, United States

    Olivia D Lara, MD
    Recruiting
  • Unc Health Cancer Care, A Service of Unc Hospitals (wakefield)

    Raleigh, North Carolina, United States

    Olivia D Lara, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anti-PD1 agent therapy - 1 yearAnti-PD1 agent therapy - 2 years
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Sept 2026
Primary completion
31 Oct 2032
Completion
31 Oct 2032
Last update posted
5 Nov 2026
Registered enrollment
140
Registry id
NCT07867002

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.